Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria

AIDS

Volumn 29, Issue 15, 2015, Pages 2035-2044

  Mitchell, Kate M ^a,g   Lépine, Aurélia ^a   Terris Prestholt, Fern ^a   Torpey, Kwasi ^b   Khamofu, Hadiza ^b   Folayan, Morenike O ^c   Musa, Jonah ^d   Anenih, James ^e   Sagay, Atiene S ^d   Alhassan, Emmanuel ^e   Idoko, John ^e   Vickerman, Peter ^f  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^d UNIVERSITY OF JOS   (Nigeria)

^e NATIONAL AGENCY FOR THE CONTROL OF AIDS   (Nigeria)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antiretroviral therapy; condom; disability adjusted life years; mathematical models; pre exposure prophylaxis; treatment as prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CELL COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; CONDOM; CONDOM USE; COST EFFECTIVENESS ANALYSIS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; NIGERIA; PRACTICE GUIDELINE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VIRUS TRANSMISSION; ADOLESCENT; ADULT; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; SERODIAGNOSIS; SEXUALITY; THEORETICAL MODEL; TRANSMISSION; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; COHORT STUDIES; CONDOMS; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NIGERIA; PRE-EXPOSURE PROPHYLAXIS; SEXUAL PARTNERS; YOUNG ADULT;

EID: 84965082032     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000798     Document Type: Article

References (40)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013.
2. UNAIDS. New HIV infections by mode of transmission in West Africa: a multicountry analysis. Geneva: UNAIDS; 2010.
3. Ezeama C, Eleje G, Okonkwo T, Ikechebelu J. Partner human immunodeficiency virus sero-discordance in Nnewi, Nigeria. J HIV Human Reprod 2014; 2:2-7.
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
6. Hendrix Craig W. Exploring concentration response in HIV preexposure prophylaxis to optimize clinical care and trial design. Cell 2013; 155:515-518.
7. Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA 2013; 310:1619-1620.
8. Kamenga M, Ryder RW, Jingu M, Mbuyi N, Mbu L, Behets F, et al. Evidence of marked sexual-behavior change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 serostatus: experience at an HIV counseling-center in Zaire. AIDS 1991; 5:61-67.
9. Rosenberg NE, Pettifor AE, De Bruyn G, Westreich D, Delany-Moretlwe S, Behets F, et al. HIV testing and counseling leads to immediate consistent condom use among South African stable HIV-discordant couples. J Acquir Immune Defic Syndr 2013; 62:226-233.
10. Roth DL, Stewart KE, Clay OJ, van der Straten A, Karita E, Allen S. Sexual practices of HIV discordant and concordant couples in Rwanda: effects of a testing and counselling programme for men. Int J STD AIDS 2001; 12:181-188.
11. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205:358-365.
12. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 2013; 27:447-458.
13. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.
14. National Population Commission (NPC) [Nigeria] and ICF Macro. Nigeria demographic and health survey 2008. Abuja, Nigeria; ICF Macro; 2009.
15. National Agency for the Control of AIDS (Nigeria). United Nations general assembly special session (UNGASS) country progress report 2008-2009. 2010.
16. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One 2010; 5:e10584.
17. Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet MA, Ajayi S, et al. Immuno-virologic outcomes and immuno-viro-logic discordance among adults alive and on antiretroviral therapy at 12 months in Nigeria. BMC Infect Dis 2013; 13:113.
18. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé J-L, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53:1283-1290.
19. Aliyu HB, Chuku NN, Kola-Jebutu A, Abubakar Z, Torpey K, Chabikuli ON. What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr 2012; 61:221-225.
20. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 62:229-243.
21. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910.
22. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473-477.
23. Kennedy-Darling J, Hoyt N, Murao K, Ross A. The energy crisis of Nigeria: an overview and implications for the future. The University of Chicago, Chicago 2008.
24. Economides MJ, Fasina A, Oloyede B. Nigeria natural gas: a transition from waste to resource. World Energy 2004; 7:134-140.
25. Centre for People and Environment and Tryby Energy Minerals and Environmental Corporation. Landfill recovery and use in Nigeria; 2010.
26. Egheosa O. What are the major risks that affect the viability of gas power plants in Nigeria and how can they be mitigated? University of Dundee; 2004.
27. World Bank. Data indicators: GDP per capita (current US$). 2013. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. [Accessed 20 May 2015]
28. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2013.
29. de Bruyn G, Martinson NA, Gray GE. Male circumcision for HIV prevention: developments from sub-Saharan Africa. Expert Rev Anti Infect Ther 2010; 8:23-31.
30. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
31. Chemaitelly H, Abu-Raddad LJ. External infections contribute minimally to HIV incidence among HIV sero-discordant couples in sub-Saharan Africa. Sex Transm Infect 2013; 89:138-141.
32. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the cost-effectiveness of preexposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5:e13646.
33. Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet 2014; 384:249-256.
34. Edejer TT-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al. WHO guide to cost-effectiveness analysis. 2012.
35. Sen A. Approaches to the choice of discount rates for social benefit-cost analysis. In Lind R, editor. Discounting for time and risk in energy policy. Baltimore: Johns Hopkins University Press; 1982. pp. 325-350.
36. Jia Z, Ruan Y, Li Q, Xie P, Li P, Wang X, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2013; 382:1195-1203.
37. Ugbena R, Aberle-Grasse J, Diallo K, Bassey O, Jelpe T, Rottinghaus E, et al. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. Clin Infect Dis 2012; 54 (Suppl 4):S375-S380.
38. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
39. Idoko J, Folayan MO, Dadem NY, Kolawole GO, Anenih J, Alhassan E. 'Why should I take drugs for your infection?': outcomes of formative research on the use of HIV preexposure prophylaxis in Nigeria. BMC Public Health 2015; 15:349.
40. 3: assessment of need following changes in treatment guidelines. Clin Infect Dis 2011; 53:817-825.